|
KMID : 0354719930170010105
|
|
Journal of Korean Diabetes Association
1993 Volume.17 No. 1 p.105 ~ p.110
|
|
|
Effects of Acipimox(Olbetam) Treatment on Plasma Lipids and Glucose in Hyperlipidemic Patients with Type 2 Diabetes Mellitus
|
|
이기업
제수정/박중열/김기수/이문호
|
|
|
Abstract
|
|
|
Background:
@EN Hypertriglyceridemia is recognized as an important atherogenic risk factor in diabetic patients. Acipimox is a new antilipolytic nicotinic acid derivative with long-lasting activity. Because of the relatively long action time, acipimox is
known
to
have less significant rebounds following interruption and no unfavorable effects on glucose metabolism during treatment.
@ES Methods:
@EN The effects of three months of acipimox treatment on glucose and lipid metabolism were evaluated in 31 patients with hypertriglyceridemic(>250㎎/dl) type 2 diabetes mellitus.
@ES Results :
@EN 1) Mean serum triglyceride concentration decreased profoundly(43%) after acipimox treatment. Less profound but significant decrease of cholesterol levels and increase of HDL-cholesterol levels were senn following acipimox therapy.
2) Mean fasting serum glucose level significantly fell after acipimox treatment. The changes in postprandial glucose and glycosylated hemoglobin were not significant.
3) One out of 31 patients experienced severe itching. In one patients, deterioration of glucose metabolism was obsered. No other laboratory abnormalities have been observed.
@ES Conclusion:
@EN Acipimox is an effective and safe drug in the treatment of hyperlipidemia in type 2 diabetes mellitus.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|